What is 950220.KQ's current stock price?

950220.KQ (NeoImmuneTech, Inc.) is currently trading at ₩2,505.00 with a market cap of ₩11.79B.

What sector is NeoImmuneTech, Inc. in?

NeoImmuneTech, Inc. (950220.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

950220.KQ NeoImmuneTech, Inc.

KOEHealthcare

₩2,505-11.48%LiveMarket Cap: ₩11.79B

As of 2026-05-18 07:45

Why 950220.KQ matters now

NeoImmuneTech, Inc. (950220.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩2,505.00 with -11.48% on the session and ₩11.79B in market capitalization.

The latest financial table shown here is Q1 2026, with revenue of ₩527.0M, net income of ₩-7.55B, and diluted EPS of ₩-234.00. Investors can compare that operating picture with valuation signals such as P/E -2.58 and FCF yield -198.4%.

InvestLog's latest related AI research is a Stock Split note titled "950220.KQ announces 1-for-5 reverse split for 2026-06-10".

Valuation

View Details

P/E (TTM)

-2.58

PEG

—

P/B

1.47

P/S

19.34

EV/EBITDA

0.49

DCF Value

—

FCF Yield

-198.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

99.9%

Operating Margin

-3829.9%

Net Margin

-5132.6%

ROE

-61.4%

ROA

-39.1%

ROIC

-35.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 2026	₩527.0M	₩-7.55B	₩-234.00
Q4 2025	₩39.1M	₩-10.77B	₩-64.26
Q3 2025	₩18.3M	₩-5.70B	₩-268.00
Q2 2025	₩25.1M	₩-7.27B	₩-371.00

Related AI Research

Stock SplitJun 4, 2026

950220.KQ announces 1-for-5 reverse split for 2026-06-10NeoImmuneTech, Inc.（950220.KQ）宣布 1:5 合股，生效日 2026-06-10

950220.KQ (NeoImmuneTech, Inc.) implemented a 1-for-5 reverse stock split on June 10, 2026, a move formally disclosed via an 8-K filing with the U.S. Securities and Exchange Commission (SEC) on May 20950220.KQ（NeoImmuneTech, Inc.）于2026年6月10日实施1:5比例的反向股票拆分，该行动已由公司于2026年5月20日向美国证券交易委员会（SEC）提交8-K表格正式披露。对于市场参与者而言，该调整将直接改变流通股数量与单股报价，但不会直接影响公司整体内在价值。

Listing Info

Market

Korea

Exchange

KOE

Currency

KRW

Sector

Healthcare

Industry

Biotechnology

Country

NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.